Over 235 Companies Worldwide Claim To Offer Contract Manufacturing Services For Various Types Of Biopharmaceutical Drug / Therapy Products

>

Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug / therapy products

Owing to the ever-increasing number of start-ups that are involved in R&D of novel biologics, there is an enormous opportunity for the CMOs in this domain. It is worth emphasizing that, since 2000, more than 115 new CMOs have been established in order to serve to the growing demand for novel biologics that have specific manufacturing requirements. The contemporary contract services market features a mix of large and small-sized CMOs and is characterized by multiple mergers and acquisitions as stakeholders strive to broaden their respective service portfolios. This has enabled several CMOs to offer end-to-end services, ranging from drug development, including preliminary R&D, preclinical and clinical trials, to commercial scale production and regulatory filings

 

To order this 750+ page report, which features 200+ figures and 250+ tables, please visit this link

 

The USD 13.9 billion (by 2030) financial opportunity within the biopharmaceutical manufacturing market has been analyzed across the following segments:

  • Commonly Outsourced Business Operations
  • Active Pharmaceutical Ingredients (API)
  • Finished Dosage Formulations (FDF)
  • Types of Expression System
  • Mammalian
  • Microbial
  • Others
  • Company Size
  • Small
  • Mid-Sized
  • Large and Very Large
  • Scale of Operation
  • Preclinical
  • Clinical
  • Commercial
  • Key Geographical Region 
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World 

 

The Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030. report features the following companies, which we identified to be key players in this domain:

  • 3P Biopharmaceuticals
  • Abzena
  • Albany Molecular Research
  • BioVectra
  • BioXcellence (Boehringer Ingelheim)
  • Celonic
  • Charles River Laboratories
  • ChemPartner
  • Cobra Biologics
  • CordenPharma
  • Cytovance Biologics
  • GE Healthcare
  • Goodwin Biotechnology
  • Grand River Aseptic Manufacturing
  • IDT Biologika
  • KBI BioPharma
  • Kemwell Biopharma
  • LFB Biomanufacturing
  • Meridian Life Science
  • Patheon
  • Pfizer CentreOne
  • PX'Therapeutics
  • Samsung BioLogics
  • Sanofi, CEPiA
  • Thermo Fisher Scientific
  • Vetter Pharma International

 

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Competitive Landscape

  4. Biopharmaceutical Contract Manufacturing in North America

  5. Biopharmaceutical Contract Manufacturing in Europe

  6. Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World

  7. Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World

 

  1. Case Study: Outsourcing of Biosimilars

  2. Case Study: Comparison of Small Molecule and Large Molecule Drugs / Therapies

 

  1. Case Study on In-House Manufacturing

  2. Collaborations

  3. Recent Developments

  4. Capacity Analysis

 

  1. Demand Analysis

 

  1. Market Forecast

 

  1. SWOT Analysis

 

  1. Future of The Biopharmaceutical CMO Market

 

  1. Survey Analysis

 

  1. Interview Transcripts

 

  1. Appendix 1: List of Non-Industry Players

 

  1. Appendix 1: List of Non-Industry Players

 

  1. Appendix 3: List of Companies and Organizations

 

To purchase a copy, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

 

Contact Details

 

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com  

Share:

Keywords: roots analysis,wellness and fitness,information services,market research,research,medical devices,pharma,healthcare,pharmaceutical,active pharmaceutical ingredient,pharmaceutical product development inc

Comments

Other related blogs

Presently, over 240 ADC therapy candidates are being evaluated in clinical / preclinical stages

By : Roots Analysis

With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer ther..


The antibody drug conjugates market is projected to grow at an annualized rate of over 20%, till 2030

By : Roots Analysis

  Roots Analysis has done a detailed report on Antibody Drug Conjugates Market, covering vario..


The antibody drug conjugates market is estimated to be worth more than 15 billion in 2030

By : Roots Analysis

  Antibody drug conjugates (ADCs) represent a transformative approach to modern cancer treatme..


The AR / VR based digital marketing service providers in healthcare sector

By : Roots Analysis

Roots Analysis has done a detailed study on “AR / VR based Healthcare Digital Marketing Servic..